Navigation Links
Roche Diabetes Care Celebrates Second Annual Infusion Site Awareness Week, Aug. 29-Sept. 4
Date:9/1/2011

INDIANAPOLIS, Sept. 1, 2011 /PRNewswire/ -- Roche Diabetes Care, makers of the ACCU-CHEK® portfolio of diabetes management products and services, is proud to host its second annual Infusion Site Awareness Week, Aug. 29-Sept. 4, a week-long effort to highlight the importance of proper infusion site management for the 400,000 people in the United States with Type 1 diabetes who use an insulin pump.

"The inaugural Infusion Site Awareness Week, which was launched during the 2010 annual American Association of Diabetes Educators (AADE) conference, helped us reach hundreds of diabetes educators and people living with Type 1 diabetes who are now better able to identify and address potential complications stemming from improper site management," said Roche Diabetes Care North America Medical Director Andreas Stuhr, M.D.

According to the Juvenile Diabetes Research Foundation (JDRF), a supporting partner for this year's campaign, as many as 3 million Americans live with type 1 diabetes, and about 15,000 children and 15,000 adults are diagnosed with the disease every year.  

"Living with type 1 diabetes requires a person to be extremely aware and knowledgeable about the disease," said Aaron Kowalski, Ph.D., Assistant Vice President of Treatment Therapies for JDRF. "In addition to monitoring blood sugar and adjusting diet and exercise, proper infusion site rotation and care is an often underemphasized, but very important part of good diabetes management. Infusion Site Awareness Week is a perfect opportunity for diabetes educators to discuss the importance of best practices for insulin pump usage with their patients, both new and old."

For people with diabetes using insulin pump therapy, the infusion site is where an insulin pump's plastic cannula or steel needle is placed under the user's skin to administer insulin. Infusion site management is the practice of choosing a site, cleaning and preparing it, properly inserting a cannula or needle, monitoring insulin flow and then regularly rotating the insertion site to avoid infection and ensure appropriate insulin delivery. In most cases, this site must be changed every one to three days and the same site must not be reused for about two weeks or until the site has fully healed.

Roche started the annual initiative last year to increase understanding and education about proper infusion site management. A 2007 study in the American Diabetes Association journal Diabetes Care reported that some adult patients experience as many as 12 issues of irritation or infection a year because of improper site maintenance. The authors concluded that "efforts to minimize the risk of irritation, scarring, and infection should include strict adherence to proper infusion site preparation, catheter insertion, and site rotation."(1)

To help increase education, Roche is distributing Infusion Site Awareness Week kits to certified diabetes educators throughout the U.S. These kits include an educational DVD explaining proper site maintenance, fact sheets to help facilitate discussions and promotional materials such as bracelets, temporary tattoos, logos and press materials to help with outreach within their communities. Information can also be found at www.infusionsitemanagement.com.

In addition to the kits, Roche is taking the conversation on infusion site management to the social web. Follow the Infusion Site Awareness movement on Twitter @infusionsite for regular updates about healthy living, diabetes management, and other important news.

"The prospect of constant finger pricks, strict diets and wearing an insulin pump all day can be devastating to newly diagnosed diabetes patients," Dr. Stuhr said. "With Infusion Site Awareness Week, we hope to make living with diabetes a little easier, a little less scary, and help people develop life-long practices that will lead to more healthy lives."

For more information, go to www.infusionsitemanagement.com.

About Roche Diabetes Care

Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients' condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management—from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems. For more information, please visit accu-chek.com.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:
Todd A. Siesky
Public Relations Manager
Roche Diabetes Care
9115 Hague Road, Building H
Indianapolis, IN 46250-0457
Phone: +1-317-521-3966
todd.siesky@roche.com
www.accu-chek.com

(1) Phillip, Moshe, MD, Battelino, Tadej , MD, PhD, Rodriguez, Henry, Danne, Thomas, MD, and Kaufman, Francine. "Use of Insulin Pump Therapy in the Pediatric Age-Group." DiabetesCare 30.6 (2007): 1653-1662.


'/>"/>
SOURCE Roche Diabetes Care
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
3. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Roche responds to announcement of IDEAL hepatitis C trial results
11. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... 16, 2017   The Harrington Discovery Institute ... Ohio , has announced the 2017 recipients ... discoveries of physician-scientists whose research shows promise to ... Harrington Discovery Institute – part of The Harrington ... need in academic medicine: to advance early breakthroughs ...
(Date:1/16/2017)... According to the new market research report "Display Controller Market by ... LCD Controller), Application (Industrial Control, Medical Equipment, Automotive, Mobile Communication), and Geography ... to grow from USD 17.26 Billion in 2015 to reach USD 32.24 ... Continue Reading ... ...
(Date:1/16/2017)... 2017 The report "Cellulose ... (Methyl, Ethyl, Hydroxyethyl, Hydroxypropyl, Carboxymethyl Cellulose), Application ... Coatings & Paints), Region - Global Forecast ... was valued at USD 4.51 Billion in ... 6.41 Billion by 2021, at a CAGR ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified ... Surgery Journal , the official journal of The American Society for Aesthetic Plastic ... surgery. The procedure is designed to correct drooping, retracted lower eyelids, which usually ...
(Date:1/16/2017)... , ... January 16, 2017 , ... One thing common ... to treat, but to test for, as well. The money spent screening for and ... Doctors in the U.S. screen patients for cancer more than in any other country ...
(Date:1/16/2017)... ... January 16, 2017 , ... Vixiar ... Officer of the medical device company, effective immediately. , “This is perfect timing ... has a strong track record in medical device market development and revenue growth, ...
(Date:1/15/2017)... , ... January 15, 2017 , ... In this role, ... the United States for the asthma & allergy friendly mark. This certification program was ... test and identify consumer products to be more suitable for the 60+ million people ...
(Date:1/15/2017)... ... ... Supply, LLC is announcing the release of an updated version of their top selling ... edition has wide jaws that will accommodate nails up to 4mm in thickness . ... handle is reinforced for extra strength when pressing down on dense nails which can be ...
Breaking Medicine News(10 mins):